Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus INDERAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus INDERAL.
BETAGAN vs INDERAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker